Physician profile
Meganne E Leach
NPI 1700933173
$13,542.10
in general payments reported to CMS, 2019-2025
6 companies · $7,719 in 2025
The $7,719 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.00 · 2022: $105 · 2023: $118 · 2024: $5,525 · 2025: $7,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,100 · Consulting Fee: $4,650 · Travel and Lodging: $2,504 · Food and Beverage: $1,048 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,100.00 |
| Consulting Fee | $4,650.00 |
| Travel and Lodging | $2,504.49 |
| Food and Beverage | $1,047.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $6,626.93 | 2022-2025 | Elevidys |
| Catalyst Pharmaceuticals, INC. | $5,284.21 | 2024 | |
| Itf Therapeutics LLC | $1,274.69 | 2025 | |
| Biogen, INC. | $221.27 | 2023-2025 | Spinraza |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $75.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meganne Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.